Star Sports Medicine Co., Ltd. executed an on-market share buyback of 2,500 H shares on 13 October 2026, paying a total of HKD 0.16 million at prices ranging from HKD 59.20 to HKD 63.45 per share.

Following the transaction:

• Issued shares (excluding treasury shares) declined to 54.77 million from 54.77 million, a marginal reduction of 0.00%. • Treasury shares increased to 59,200, while the company’s total issued share count remained unchanged at 54.83 million.

The repurchase was conducted under the mandate approved on 26 June 2026, which authorises the company to buy back up to 5.48 million shares. Cumulative repurchases under this mandate now stand at 59,200 shares, equal to 0.11% of the issued share capital on the mandate date.

In line with Hong Kong Stock Exchange rules, Star Sports Medicine is subject to a moratorium on new share issues or sales of treasury shares until 12 November 2026.

The board confirms that the transaction complied with all applicable regulatory requirements and that the repurchased shares have been retained as treasury stock.